Eam Global Investors LLC Prothena Corp Public LTD CO Transaction History

Eam Global Investors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$48.26 - $78.59 $374,111 - $609,229	7,752 Added 12.28%	70,872 $4.84 Million
Q1 2023 May 12, 2023	SELL	$46.97 - $58.27 $635,645 - $788,567	-13,533 Reduced 17.65%	63,120 $3.06 Million
Q3 2022 Nov 14, 2022	BUY	$25.16 - $60.63 $1.93 Million - $4.65 Million	76,653 New	76,653 $4.65 Million
Q4 2021 Feb 11, 2022	SELL	$42.11 - $73.26 $2.09 Million - $3.64 Million	-49,720 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$48.2 - $78.89 $989,787 - $1.62 Million	-20,535 Reduced 29.23%	49,720 $3.54 Million
Q2 2021 Aug 13, 2021	SELL	$21.63 - $57.65 $359,166 - $957,278	-16,605 Reduced 19.12%	70,255 $3.61 Million
Q1 2021 May 11, 2021	BUY	$11.0 - $28.24 $955,460 - $2.45 Million	86,860 New	86,860 $2.18 Million

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $714M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Eam Global Investors LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Global Investors LLC with notifications on news.